<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335280</url>
  </required_header>
  <id_info>
    <org_study_id>15-17319</org_study_id>
    <nct_id>NCT03335280</nct_id>
  </id_info>
  <brief_title>68Ga-citrate PET/MR Imaging for Glioma</brief_title>
  <official_title>68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, Phase 2, single center, open-label study in adult patients with
      presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of
      care. In some cases, patients will have had biopsy. Study participants will undergo
      68Ga-citrate PET/MR prior to surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax</measure>
    <time_frame>1 day</time_frame>
    <description>The location and extent of 68Ga-citrate uptake will be compared to both same day MRI and subsequent pathology. SUVmax will be the outcome of interest and summarized with descriptive measures. SUVmax will be compared via a two-sided two-sample equal-variance ttest between those patients positive for PTEN deletion and those negative for PTEN deletion.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Positive for PTEN deletion</arm_group_label>
    <description>Confirmed by immunohistochemistry of tissue biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative for PTEN deletion</arm_group_label>
    <description>Confirmed by immunohistochemistry of tissue biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-citrate PET/MR</intervention_name>
    <description>Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.</description>
    <arm_group_label>Positive for PTEN deletion</arm_group_label>
    <arm_group_label>Negative for PTEN deletion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with WHO grade 3 or 4 glioma planning to undergo surgery with availability of
        immunohistochemistry of tissue
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO grade 3 or 4 glioma planning to undergo surgery

          -  Age &gt;= 18 years

          -  Karnofsky performance status of &gt;= 60

          -  Ability to understand a written informed consent document, and the willingness to sign
             it

        Cohort A - 20 subjects

          -  Positive for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy Cohort
             B - 20 subjects

          -  Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

        Exclusion Criteria:

          -  Contraindications to PET imaging (e.g. pregnant or breast-feeding woman)

          -  Contraindications to MR imaging (e.g. pacemakers, metallic implants, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Evans, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Gao, BS</last_name>
    <phone>415-353-9437</phone>
    <email>kenneth.gao@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dora Tao, BS</last_name>
    <phone>415-514-6759</phone>
    <email>dora.tao@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Gao, BS</last_name>
      <phone>415-353-9437</phone>
      <email>kenneth.gao@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dora Tao, BS</last_name>
      <phone>415-514-6759</phone>
      <email>dora.tao@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Evans, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Spencer Behr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchel Berger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Braunstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soonmee Cha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Flavell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Hess, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Villanueva-Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Nelson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Molinaro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97-109. Epub 2007 Jul 6. Review. Erratum in: Acta Neuropathol. 2007 Nov;114(5):547.</citation>
    <PMID>17618441</PMID>
  </reference>
  <reference>
    <citation>Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008 Jul 31;359(5):492-507. doi: 10.1056/NEJMra0708126. Review. Erratum in: N Engl J Med. 2008 Aug 21;359(8):877.</citation>
    <PMID>18669428</PMID>
  </reference>
  <reference>
    <citation>Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015 Oct;11(10):556-66. doi: 10.1038/nrneurol.2015.171. Epub 2015 Sep 15. Review.</citation>
    <PMID>26369507</PMID>
  </reference>
  <reference>
    <citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.</citation>
    <PMID>20231676</PMID>
  </reference>
  <reference>
    <citation>Juhász C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00015. Review.</citation>
    <PMID>24825818</PMID>
  </reference>
  <reference>
    <citation>Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20.</citation>
    <PMID>25411133</PMID>
  </reference>
  <reference>
    <citation>Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015 Sep;17(9):1293-300. doi: 10.1093/neuonc/nov088. Epub 2015 May 24.</citation>
    <PMID>26008606</PMID>
  </reference>
  <reference>
    <citation>Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C, Galldiks N, Tellmann L, Weiss C, Sabel M, Coenen HH, Shah NJ, Langen KJ. Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015 Oct;25(10):3017-24. doi: 10.1007/s00330-015-3691-6. Epub 2015 Mar 27.</citation>
    <PMID>25813014</PMID>
  </reference>
  <reference>
    <citation>Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology. 2014 Dec;273(3):831-43. doi: 10.1148/radiol.14132868. Epub 2014 May 30.</citation>
    <PMID>24885857</PMID>
  </reference>
  <reference>
    <citation>Verma N, Cowperthwaite MC, Burnett MG, Markey MK. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013 May;15(5):515-34. doi: 10.1093/neuonc/nos307. Epub 2013 Jan 16. Review.</citation>
    <PMID>23325863</PMID>
  </reference>
  <reference>
    <citation>Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, Herzog H, Shah NJ, Fink GR, Coenen HH, Langen KJ. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med. 2012 Sep;53(9):1367-74. doi: 10.2967/jnumed.112.103325. Epub 2012 Aug 7.</citation>
    <PMID>22872742</PMID>
  </reference>
  <reference>
    <citation>Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42. Epub 2007 Sep 1.</citation>
    <PMID>17763848</PMID>
  </reference>
  <reference>
    <citation>Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen HH, Schober O. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9. Epub 2005 Jan 14.</citation>
    <PMID>15650870</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael Evans</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

